SEC Filing Summary: Greatbatch, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Greatbatch, Inc. on November 30, 2015. The report addresses a significant regulatory milestone rather than routine financial reporting. The Company is based in Frisco, Texas, and operates in the medical device sector.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statements or performance data.
Material Changes
The primary material event reported is the receipt of Premarket Approval (PMA) from the United States Food & Drug Administration (FDA) for the Company's Algovita spinal cord stimulation system. This approval covers the treatment of chronic pain in the trunk and limbs. Management characterizes this as a strategic evolution of product offerings to include the development of complete medical devices.
Outlook and Management Commentary
Management views the FDA approval as a pivotal step in expanding the Company's capabilities beyond components to full medical device systems. No specific financial guidance, risk factors, or contingencies related to this event were detailed in the text of this specific filing.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed product specifications and commercialization plans.
- Confirm the timeline for the commercial launch of the Algovita spinal cord stimulation system.
- Review subsequent quarterly reports (10-Q) or annual reports (10-K) to assess the financial impact of this new product line.
- Check for any post-approval conditions or restrictions imposed by the FDA.